vanadium
transit
metal
ubiquit
distribut
soil
crude
oil
water
air
also
found
role
biolog
system
essenti
element
live
be
also
sever
group
organ
accumul
vanadium
employ
biolog
process
vanadium
biolog
relev
element
surpris
mani
vanadium
base
therapeut
drug
propos
treatment
sever
type
diseas
name
vanadium
compound
particular
organ
deriv
propos
treatment
diabet
cancer
diseas
caus
parasit
work
review
medicin
applic
propos
vanadium
compound
particular
emphasi
recent
public
cell
partli
due
similar
vanad
phosphat
vanadium
compound
activ
numer
signal
pathway
transcript
factor
potenti
applic
vanadiumbas
therapeut
nevertheless
nonspecif
bioactiv
may
also
introduc
sever
deleteri
side
effect
addit
due
fenton
type
reaction
reaction
atmospher
vc
may
also
gener
reactiv
oxygen
speci
therebi
introduc
oxid
stress
consequ
present
well
evalu
particularli
longterm
progress
chemistri
vanadium
name
search
therapeut
applic
exponenti
last
year
sever
review
publish
last
five
year
well
other
distinct
area
well
cover
recent
review
work
make
review
medic
applic
vanadium
complex
tri
systemat
cover
public
make
comprehens
text
recent
book
edit
michibata
includ
chapter
vanadium
effect
bone
metabol
vanadium
cancer
prevent
cardiovascular
protect
vanadium
compound
inhal
toxic
vanadium
thu
topic
shortli
address
consid
rel
element
abund
planet
crust
vanadium
element
thu
far
zinc
ubiquit
distribut
soil
fossil
particularli
crude
oil
water
air
live
organ
sea
water
vanadium
exist
mainli
form
h
vo
abund
transit
element
two
order
magnitud
abund
iron
usual
v
concentr
drink
water
nm
rang
groundwat
volcan
area
may
contain
much
higher
amount
ca
contamin
frequent
observ
river
lake
sea
refer
therein
mani
metal
ion
gener
tendenc
interact
biomolecul
therefor
surpris
natur
evolut
incorpor
mani
perform
wide
varieti
task
play
crucial
role
live
be
sinc
natur
made
extens
use
metal
ion
question
metal
ion
incorpor
drug
coordin
chemistri
use
advantag
medicin
purpos
natur
aris
subject
medicin
inorgan
chemistri
vanadium
ubiquit
present
planet
crust
also
found
role
biolog
system
work
focus
potenti
use
vanadiumbas
therapeut
compound
medicin
sever
group
organ
accumul
vanadium
andor
employ
vanadium
life
process
basi
high
amount
found
earth
crust
name
prebiot
condit
life
first
appear
known
use
biochemistri
vanadium
like
essenti
role
live
be
name
human
averag
vanadium
concentr
human
bodi
approxim
equilibrium
amount
excret
bodi
constant
suppli
vanadium
via
food
drink
water
may
easili
maintain
main
rout
vanadium
uptak
distribut
human
bodi
sketch
fig
adapt
nonoccup
vanadium
exposur
predominantli
food
suppli
typic
daili
dose
consum
human
estim
mg
vday
dietari
uptak
quit
ineffect
process
dietari
vanadium
usual
excret
fece
see
main
natur
sourc
vanadium
load
atmospher
continent
dust
evolv
weather
soil
marin
aerosol
volcan
emiss
major
sourc
aerial
contamin
mine
industri
enterpris
burn
crude
oil
nonpollut
area
concentr
vanadium
oxid
vox
rang
ng
pollut
combust
petroleum
oil
main
contributor
aerial
vox
rais
v
level
ng
urban
industri
area
particular
worker
exposur
vanadium
larg
result
inhal
vanadium
pentoxid
workplac
dust
respiratori
effect
common
problem
thereof
mani
organ
suffer
advers
effect
vanadium
oxid
readili
absorb
lung
solubil
form
vanad
h
vo
enter
blood
stream
maximum
allow
concentr
breath
air
amount
mg
case
onetim
exposur
limit
valu
immedi
danger
health
averag
human
mg
vanadium
intraven
applic
mg
v
breath
air
inhal
normal
food
constitut
potenti
hazard
averag
content
v
food
ca
g
kg
noeffect
level
oral
intak
mg
kg
per
day
relev
refer
see
costa
pessoa
tomaz
two
volum
vanadium
environ
chapter
inhal
toxic
vanadium
assem
levi
review
olopad
connor
refer
provid
therein
mani
studi
develop
vitro
experiment
anim
model
reveal
vanadium
compound
display
insulin
mimet
properti
mitogen
effect
stimulatori
inhibitori
action
cell
differenti
numer
metabol
effect
vitro
studi
cellfre
system
shown
effect
vanadium
deriv
activ
mani
enzym
especi
relat
phosphat
reaction
vanadium
inhibit
sever
atpas
differ
potenc
moreov
vanadium
compound
also
inhibit
differ
phosphatas
alkalin
phosphatas
acid
phosphatas
tyrosineprotein
phosphatas
enzym
inhibit
vanadium
ribonucleas
phosphodiesteras
phosphoglucomutas
ptpase
activ
inhibit
intracellular
signal
pathway
trigger
differ
biolog
effect
cascad
way
biolog
system
level
phosphoril
protein
balanc
activ
kinas
phosphatas
show
type
enzym
import
role
regul
cellular
process
phosphatas
hydrolyz
phosphoprotein
classifi
two
group
affin
serinethreonin
phosphat
protein
pstpase
affin
tyrosinephosph
protein
ptpase
catalyz
hydrolysi
phosphat
ester
pstpase
metalloenzym
produc
direct
attack
water
molecul
p
atom
substrat
contrari
ptpase
metalloenzym
activ
site
cystein
residu
catalyt
mechan
fosfocystein
form
intermedi
moreov
enzym
structur
mechanist
differ
acid
alkalin
phosphatas
well
hydrol
phosphateest
small
molecul
vanadium
compound
oxid
cystein
residu
format
free
radic
regul
way
mani
biolog
event
alkalin
phosphatas
bound
membran
glycoprotein
codifi
differ
gene
classifi
specif
tissu
phosphatas
nonspecif
tissu
phosphatas
enzym
hydrolyz
phosphat
monoest
small
molecul
protein
catalyz
transfer
phosphat
group
hydroxyl
group
organ
molecul
mechan
action
occur
phosphoryl
serin
residu
activ
site
follow
transfer
phosphat
group
water
molecul
organ
acceptor
abil
vanadium
inhibit
enzym
close
relat
physicochem
properti
vanad
phosphat
see
section
structur
vanad
similar
phosphat
import
emphas
vanad
show
greater
flexibl
coordin
geometri
anion
particip
similar
reaction
gener
stabl
transit
state
vanad
enzym
consid
reason
inhibitori
effect
enzym
activ
studi
xray
diffract
demonstr
vanad
bind
activ
site
enzym
trigon
bipyramid
geometri
assay
vanadium
compound
differ
coordin
geometri
suggest
complex
five
coordin
potent
inhibitor
coordin
number
six
seven
nevertheless
factor
affect
enzymat
activ
v
iv
cation
also
inhibit
differ
enzym
case
greater
potenc
vanad
one
propos
mechan
inhibit
base
possibl
v
iv
adopt
trigon
bipyramid
bind
activ
site
enzym
thu
caus
inhibit
activ
case
enzym
activ
vanadium
follow
indirect
mechan
vanadium
stimul
enzym
activ
format
complex
ligand
resembl
structur
physiolog
substrat
instanc
dehydrogenas
activ
vanad
anoth
mechan
regul
enzymat
activ
relat
enzym
activ
inhibit
phosphoryl
tyrosin
residu
vanad
also
form
ester
tyr
residu
mimick
phosphoryl
process
great
impact
sever
biolog
event
activ
vanad
cytosol
kinas
insulin
receptor
ir
impact
balanc
phosphorylationdephosphoryl
process
vitro
experi
cell
cultur
show
vc
may
caus
enhanc
insulin
mimet
action
stimul
protein
phosphoryl
tyr
residu
increas
level
phosphoinositid
stimul
cell
prolifer
differ
cell
line
promot
uptak
small
molecul
ion
etc
contrari
vanadium
compound
also
exhibit
antitumor
effect
well
toxic
transform
action
differ
cell
line
moreov
worthi
know
global
underli
mechan
action
vanadium
compound
still
poorli
understood
vanadium
compound
wellknown
antidiabet
effect
glucos
lipid
metabol
mechan
still
complet
understood
previous
report
vo
acac
vo
maltolato
navo
attenu
basal
lipolysi
adipocyt
assess
glycerol
releas
marker
lipolysi
though
akt
erk
pathway
activ
vc
akt
activ
three
vanadium
compound
play
role
antilipolyt
effect
hand
vo
acac
block
cell
cycl
progress
phase
via
highli
activ
erk
signal
pathway
human
hepatoma
cell
result
indic
similar
activ
pathway
may
lead
differenti
biolog
consequ
cancer
cell
adipocyt
indic
vc
may
use
prevent
treatment
diabet
cancer
action
insulin
depend
bind
hormon
receptor
activ
transduct
signal
involv
seri
protein
kinas
mapk
kinas
well
lipid
kinas
insulin
mimet
effect
vanadium
may
caus
stimul
autophosphoryl
insulin
receptor
differ
manner
hormon
effect
depend
tissu
anim
speci
instanc
rat
lung
cell
rabbit
mous
diaphragm
cell
vanadium
caus
autophosphoryl
insulin
receptor
hand
inhibit
tyrosin
kinas
activ
insulin
receptor
vanad
suppress
effect
vanad
glucos
metabol
suggest
postreceptor
action
vc
show
insulinlik
effect
stimul
kinas
signal
transduct
pathway
use
insulin
beyond
ir
mapk
cho
cell
express
insulin
receptor
vanad
oxidovanadium
iv
stimul
phosphoryl
protein
insulin
pathway
erk
turn
phosphoryl
regul
action
transcript
factor
mani
relat
cell
prolifer
enzym
regul
metabol
mitogen
effect
insulin
vanadium
promot
activ
enzym
moreov
activ
pathway
rasmapk
voso
seem
depend
activ
hand
swiss
mous
fibroblast
vanad
stimul
ribosom
kinas
result
support
hypothesi
ptpase
inhibit
may
main
mechan
vanadium
compound
exert
insulin
mimet
insulin
enhanc
effect
also
suggest
vanad
may
caus
insulin
effect
activ
cytosol
kinas
cytptk
consid
altern
via
promot
insulin
like
effect
anoth
interest
field
effect
vanadium
cell
prolifer
differenti
growth
factor
stimul
cell
prolifer
though
activ
differ
receptor
turn
trigger
intracellular
signal
pathway
promot
action
differ
transcript
factor
insulin
stimul
rasmapk
pathway
sequenc
cascad
event
insulin
exert
mitogen
action
way
differ
agent
abl
activ
signal
transduct
pathway
insulin
caus
cellular
prolifer
differ
vitro
studi
cell
cultur
demonstr
vc
display
biphas
behavior
toward
mitogenesi
concentr
usual
enhanc
cell
prolifer
concentr
inhibit
event
vanad
stimul
dna
synthesi
fibroblast
behav
growth
factor
mimet
agent
promot
transit
cell
phase
cell
cycl
moreov
vanad
potenti
prolif
effect
igfi
osteoblast
cultur
mitogen
dose
vanad
also
show
dosedepend
increas
alkalin
phosphatas
marker
matur
osteoblast
cultur
calvari
cell
stimul
bone
collagen
synthesi
differ
v
iv
ocomplex
organ
ligand
regul
osteoblast
differenti
display
stimulatori
action
collagen
type
synthesi
mitogen
action
vanadium
compound
may
mediat
mak
pathway
fact
previous
mention
v
indirectli
activ
kinas
erk
sequenti
activ
erk
promot
action
transcript
factor
convey
cell
enter
cell
cycl
activ
also
relat
mitogen
action
vanadium
cross
two
pathway
activ
pkb
way
support
mitogen
action
vc
pathway
activ
vanadium
may
relat
prolif
effect
phosphoinositid
heterotrimer
protein
g
v
increas
level
inositol
mono
diand
triphosph
mechan
depend
nondepend
tyrosin
kinas
hand
case
vanad
stimul
protein
g
pathway
high
concentr
mm
concentr
high
compar
caus
prolif
effect
cell
cultur
report
cantley
et
al
endogen
vanad
inhibit
na
k
atpas
vitro
made
sinc
mani
physiolog
role
ascrib
vanadium
mitogen
action
stimul
bone
cell
prolifer
bone
collagen
synthesi
noradrenalin
releas
pulmonari
arteri
inhibit
oxid
drug
demethyl
stimul
oncogen
express
histamin
releas
mast
cell
well
toxic
cytostat
action
antidiabet
action
neoplast
transform
possibl
vanadium
compound
vc
may
regul
osteogenesi
possibl
abl
counteract
bone
damag
action
glucocorticoid
also
suggest
mention
one
relev
prospect
role
vc
diabet
mellitu
dm
treatment
import
featur
vanadium
insulin
mimet
im
action
multipl
effect
review
eg
spontan
chemic
induc
diabet
anim
vanadium
allevi
primari
symptom
diabet
high
blood
glucos
triglycerid
cholesterol
level
although
tissu
vanadium
level
normal
correl
glucoselow
effect
also
prevent
revers
sever
secondari
complic
sorbitol
accumul
cataract
develop
impair
thyroid
hormon
alter
kidney
morpholog
adren
hypertrophi
partial
pancreatectom
rat
vanadium
administr
revers
insulin
resist
restor
muscl
glycogen
synthesi
stzdiabet
rat
stimul
basal
hexos
uptak
muscl
liver
even
nondiabet
rat
muscl
vanadium
therapi
increas
sensit
insulin
stimul
glycolysi
glycogen
synthesi
impair
antioxid
statu
excess
food
fluid
intak
also
report
vanad
prevent
declin
cardiac
perform
due
diabet
cardiomyopathi
streptozotocininduc
stz
diabet
rat
isol
work
heart
paramet
left
ventricular
develop
pressur
rate
pressur
develop
also
indic
bmov
fig
administr
result
signific
attenu
heart
dysfunct
sinc
secondari
complic
diabet
known
increas
oxid
stress
etiolog
compon
possibl
vanadium
insulin
mimesi
partial
due
chang
prooxidantoxid
balanc
also
consid
imbal
product
ro
function
antioxid
defens
associ
sever
patholog
condit
eg
cardiovascular
diseas
rheumatoid
osteoarthr
diabet
mellitu
tumor
angiogenesi
prolifer
cataract
format
inflamm
curcumin
compound
known
neuroprotect
action
demonstr
efficaci
patholog
condit
vo
cur
effect
anticanc
agent
compar
uncomplex
curcumin
voso
alon
twice
effect
curcumin
alon
antiarthrit
agent
four
time
effect
curcumin
alon
inhibit
smooth
muscl
cell
prolifer
probabl
relev
aspect
deserv
care
neither
curcumin
vo
cur
effect
reduc
plasma
glucos
level
stzdiabet
rat
contrast
report
capac
curcumin
facilit
lower
plasma
glucos
decreas
insulin
resist
differ
might
experi
thompson
et
al
obtain
upon
acut
oral
administr
curcumin
vo
cur
data
research
oral
gavag
daili
basi
week
curcumin
stz
rat
dbdb
diabet
mice
one
interest
compound
vo
alx
compound
fig
group
sakurai
prepar
sever
vc
evalu
biolog
function
vitro
vivo
demonstr
whether
administr
acut
oral
gavag
acut
ip
inject
vo
alx
could
one
promis
complex
treatment
diabet
pharmacolog
function
vo
alx
includ
hypoglycem
effect
improv
hyperinsulinemia
hypercholesterolemia
hypertens
vo
alx
significantli
induc
v
uptak
insulinrespons
tissu
adipos
liver
muscl
tissu
vo
alx
also
affect
tyrosin
phosphoryl
ir
lead
activ
signal
transloc
plasma
membran
moreov
also
demonstr
vo
alx
regul
dna
bind
activ
transcript
factor
turn
control
express
gluconeogenesi
gene
respons
akt
activ
overal
vo
alx
improv
diabet
obes
hypertens
enhanc
insulin
sensit
leptin
resist
obesitylink
type
diabet
kkay
mice
propos
promis
vc
treat
type
obesitylink
type
diabet
final
comment
reader
also
consid
interest
review
aureliano
cran
summar
protein
interact
vanad
give
focu
decavanad
show
vanad
biolog
effect
due
monomer
vanad
name
decavanad
interact
polyphosph
nucleotid
inositol
bind
site
enzym
concern
applic
vc
therapeut
agent
treatment
diabet
one
main
focus
fact
vanadium
compound
report
exhibit
insulinlik
effect
among
vc
test
small
molecul
insulinmimet
insulinenhanc
v
iv
maltolato
glucos
level
streptozotocininduc
stz
diabet
rat
beov
complet
phase
iia
clinic
trial
although
essenti
success
clinic
trial
provision
abandon
exampl
vc
report
potenti
antitumor
agent
inorgan
complex
metvan
vcystein
complex
semicarbazon
deriv
vo
acac
see
section
sever
vc
also
report
prospect
use
antiparasit
spermicid
antivir
antihiv
antituberculosi
agent
see
vanadium
also
enter
blood
stream
inject
infus
either
intent
inject
intraven
intraperiton
accident
present
contamin
infus
solut
besid
speciat
vanadium
compound
end
blood
stream
either
resorpt
gastrointestin
tract
via
lung
infusioninject
subject
redox
interconvers
v
v
v
iv
depend
oxygen
tension
presenc
redoxact
agent
main
transport
blood
anion
vanad
v
cation
v
iv
neutral
charg
v
iv
ol
speci
transfer
valu
rang
nm
determin
vanadium
concentr
human
blood
plasma
upon
oral
treatment
human
patient
vc
concentr
v
blood
serum
depend
regim
amount
compound
given
much
higher
valu
report
ca
rat
treat
bmov
beov
fig
maximum
valu
ca
found
blood
plasma
plasma
vanadium
content
rat
may
consid
declin
three
phase
phase
rapid
declin
halflif
h
follow
second
intermedi
declin
h
third
slow
one
day
vanadium
content
blood
thu
reduc
within
first
h
clear
occur
directli
via
urinari
excret
well
distribut
tissu
vanadium
found
urin
ca
day
resid
time
vanadium
bone
may
replac
phosphoru
hydroxyapatit
ca
month
correspond
halflif
day
vanadium
biolog
system
may
present
oxid
state
iii
v
iii
iv
v
iv
v
v
v
mammal
v
iv
v
v
normal
consid
relev
v
iii
suscept
oxid
howev
v
iii
htf
speci
htf
human
serum
transferrin
report
quit
airstabl
low
concentr
present
blood
plasma
v
v
exist
mainli
h
vo
hvo
often
refer
vo
monovanad
ph
low
concentr
v
v
blood
plasma
sever
potenti
ligand
present
expect
divanad
v
tetravanad
cv
might
form
cell
usual
physiolog
vanad
concentr
also
low
allow
format
oligovanad
local
howev
concentr
enhanc
templatedirect
nucleat
may
take
place
oligovanad
form
interact
protein
dna
cellular
target
process
probabl
affect
decavad
membran
depolar
pump
channel
receptor
cellular
membran
endoplasm
reticulum
membran
contractil
system
cytoskeleton
structur
function
mitochondria
bioenerget
ross
speci
chang
antioxid
respons
probabl
also
nucleou
v
iv
normal
exist
v
iv
ospeci
v
iv
quit
suscept
oxid
ph
form
insolubl
hydroxid
ph
k
sp
ph
oligomer
vanadium
speci
may
relev
even
concentr
low
nm
see
fig
blood
serum
probabl
v
iv
total
bound
high
molecular
mass
low
molecular
mass
bioligand
also
present
insid
cell
mani
bioligand
present
form
complex
v
iv
bind
constant
probabl
higher
thu
v
iv
also
bound
howev
presenc
small
amount
v
iv
oh
free
bound
rule
relev
physiolog
media
taken
account
monovanad
phosphat
structur
analog
monovanad
slightli
larger
phosphat
see
fig
geometr
point
view
two
anion
much
differ
vanad
v
thu
competitor
phosphat
site
commonli
occupi
phosphat
howev
also
signific
differ
exist
approxim
equal
amount
phosphoru
attain
coordin
number
transit
state
vanadium
much
versatil
respect
easili
form
stabl
complex
coordin
number
therefor
incorpor
activ
site
phosphatedepend
enzym
take
place
phosphat
activ
enzym
inhibit
present
solid
basi
categor
vc
depict
fig
harm
administ
reason
amount
instead
mention
vanadium
form
h
vo
probabl
involv
regul
phosphatedepend
process
metabol
process
involv
phosphatas
kinas
phosphat
metabol
gener
thu
probabl
vanadium
essenti
element
plausibl
regulatori
role
vanadium
certainli
relat
structur
chemic
similar
phosphat
vanad
see
fig
addit
particip
v
iv
v
v
level
reactiv
oxygen
speci
ro
suggest
vanadium
benefici
treatment
sever
diseas
malfunct
relat
ro
imbal
competit
behavior
vanad
respect
phosphat
like
clue
insulinmimeticinsulinenhanc
effect
vc
mention
ph
low
concentr
free
v
iv
exist
significantli
v
iv
oh
structur
simi
interconvers
v
iv
v
v
thu
fast
easi
physiolog
condit
suggest
besid
monovanad
v
v
iv
oh
may
also
mimic
phosphat
blood
stream
blood
serum
constitu
probabl
domin
vanadium
speciat
consequ
final
cellular
uptak
tissu
cell
target
pathway
vanadium
speciat
encompass
ligand
exchang
andor
redoxinterconvers
v
v
v
iv
potenti
v
iii
ligand
exchang
low
molecular
mass
constitu
lactat
citrat
high
molecular
mass
constitu
transferrin
htf
albumin
immunoglobulin
g
import
one
htf
predomin
role
reduc
agent
ascorb
glutathion
nadh
induc
reduct
v
v
v
iv
oxid
vanadium
introduc
blood
form
prospect
drug
composit
v
iv
ol
n
exampl
complex
fig
part
vanadium
may
cross
membran
erythrocyt
cell
v
v
reduc
v
iv
cellular
glutathion
bind
hemoglobin
vanadium
compound
remain
blood
plasma
may
bind
htf
form
either
type
type
speci
see
fig
form
v
iv
htf
holohtf
fe
iii
htf
protein
close
conform
thu
recogn
transferrin
receptor
cell
membran
fe
iii
uptaken
cell
fe
iii
htf
receptormedi
endocytosi
process
regard
cellular
uptak
vanadium
present
prospect
drug
composit
v
iv
ol
n
sever
scenario
appli
uptak
process
complex
stabl
enough
remain
intact
suffici
lipophil
slowli
cross
cellular
membran
via
diffus
pyridinon
complex
fig
enter
erythrocyt
diffus
name
v
iv
htf
probabl
recogn
cellular
htf
receptor
intern
via
endocytosi
inform
avail
regard
v
iv
l
htf
case
probabl
htf
form
close
conform
requir
adequ
bind
cell
receptor
either
v
iv
vanad
v
iv
l
n
speci
bind
holohtf
avail
donor
atom
protein
speci
probabl
recogn
cellular
htf
receptor
intern
via
endocytosi
v
iii
speci
may
form
eg
v
iii
htf
v
iii
fe
iii
htf
form
close
conform
probabl
recogn
cellular
htf
receptor
also
intern
via
receptormedi
endocytosi
complex
stabl
enough
remain
intact
contain
one
function
outer
coordin
sphere
recogn
cell
receptor
receptormedi
uptak
potenti
transport
rout
albumin
receptor
cell
eg
adipocit
surfac
would
also
like
vehicl
vc
bind
hsa
also
report
human
serum
albumin
hsa
enhanc
insulinlik
activ
vc
transferrin
vc
increas
tyrosin
phosphoril
respons
insulin
includ
may
due
enhanc
uptak
cell
subject
deserv
studi
aim
clinic
use
vc
futur
organ
distribut
metallokinet
featur
vanadium
well
sourc
adapt
ref
correspond
complex
form
well
understood
purpos
neutron
activ
analysi
naa
one
import
techniqu
use
determin
total
vanadium
level
organ
rat
given
voso
vc
differ
coordin
mode
rat
treat
voso
vanadium
found
kidney
liver
bone
pancrea
rat
treat
vc
vo
fig
detect
bone
kidney
spleen
liver
pancrea
differ
organ
distribut
voso
vc
might
suggest
longact
charact
complex
vanadium
level
week
bmov
supplement
compar
obtain
week
voso
feed
daili
bmov
dose
taken
half
bmov
treatment
diabet
rat
concentr
mgml
drink
water
result
accumul
v
bone
kidney
liver
muscl
fat
without
mortal
period
decreas
plasma
glucos
ghb
triglycerid
cholesterol
bmov
therapi
effect
prevent
develop
myocardi
dysfunct
associ
stzinduc
diabet
rat
even
rat
whose
blood
glucos
level
remain
normal
total
vanadium
distribut
stzrat
treat
vo
also
examin
naa
method
v
accumul
almost
tissu
particularli
bone
kidney
mitochondri
fraction
liver
supernat
kidney
stzrat
receiv
vo
ip
inject
similar
tendenc
observ
vanadium
distribut
stzrat
given
vc
oral
administr
except
accumul
mitochondri
fraction
liver
v
accumul
bone
rat
receiv
ip
inject
vo
remark
time
kidney
time
liver
result
somewhat
similar
distribut
vanadium
rat
treat
ip
inject
vo
pic
accumul
bone
approxim
time
kidney
time
liver
rat
treat
complex
vo
naa
radioisotop
determin
v
found
kidney
liver
bone
pancrea
stz
rat
treat
vo
daili
ip
inject
day
without
administr
vc
addit
day
organ
distribut
total
v
bone
molg
wet
tissu
kidney
spleen
adipos
liver
pancrea
lung
heart
blood
cell
serum
brain
longterm
action
vo
vc
oral
administr
probabl
relat
accumul
v
mainli
bone
vanadium
accumul
bone
may
releas
gradual
organ
via
bloodstream
stop
administr
vc
abl
normal
blood
glucos
level
long
period
access
metallokinet
featur
vo
complex
group
sakurai
appli
bcmepr
method
allow
trace
paramagnet
speci
blood
fig
exampl
vc
given
singl
iv
inject
rat
c
anesthesia
pentobarbit
v
iv
epr
spectra
measur
room
temperatur
everi
conclud
major
factor
disappear
epr
signal
circul
blood
due
vc
particip
redox
process
vo
speci
circul
blood
distribut
tissu
elimin
bodi
thu
v
iv
speci
taken
blood
distribut
shortand
longstay
tissu
accumul
redistribut
bone
liver
kidney
realtim
epr
analysi
v
iv
speci
reveal
term
halflif
clearanc
rate
blood
rat
given
voso
higher
given
vc
min
voso
treat
rat
min
vctreat
rat
slow
clearanc
rate
vc
suggest
higher
distribut
vanadium
rat
organ
obtain
turn
indic
longterm
act
normoglycem
effect
upon
stop
v
administr
scheme
depict
vivo
blood
circul
monitoringelectron
paramagnet
reson
bcmepr
studi
rat
carri
method
use
measur
realtim
disposit
spin
probe
circul
blood
rat
sourc
reproduc
permiss
ref
slow
elimin
v
circul
blood
rat
indic
differ
associ
vc
blood
compon
serum
protein
erythrocyt
rat
given
vo
given
vc
metallokinet
analysi
conclud
v
iv
speci
tend
distribut
peripher
tissu
gradual
elimin
circul
blood
vc
electronwithdraw
donat
group
remain
significantli
higher
level
longer
due
slower
clearanc
rate
blood
suggest
high
exposur
longer
resid
vc
associ
higher
normoglycem
effect
diabet
anim
vitro
im
activ
metallokinet
charact
vivo
antidiabet
action
vopicolin
complex
thu
appear
relat
chemic
structur
vanadium
also
accumul
almost
tissu
especi
bone
kidney
liver
pancrea
rat
given
vo
pyd
subcellular
distribut
vanadium
rat
treat
vo
pyd
voso
vanadium
found
abundantli
supernat
fraction
kidney
three
fraction
signific
differ
vanadium
distribut
found
hepat
distribut
vanadium
rat
treat
voso
differ
rat
treat
vo
pyd
highest
vanadium
concentr
determin
mitochondri
fraction
liver
rat
treat
voso
distribut
vanadium
show
signific
differ
among
four
fraction
rat
treat
vo
pyd
bmov
voso
disappear
vanadium
fastest
blood
slowest
bone
follow
kidney
liver
rel
slow
clearanc
v
plasma
may
attribut
vanadium
recircul
also
seen
much
smaller
dose
v
oral
gavag
disappear
vanadium
fastest
soft
tissu
h
versu
h
slowest
bone
day
nh
vo
versu
day
beov
chronic
administr
vocompound
lead
bone
tissu
accumul
highest
amount
vanadium
suggest
made
v
probabl
form
vanad
v
substitut
phosphat
miner
hydroxyapatit
structur
bone
howev
measur
bone
tissu
paramagnet
indic
also
contain
v
iv
ospeci
v
iv
may
substitut
ca
mg
bone
tissu
diabet
individu
higher
incid
bone
fractur
nondiabet
one
effect
vo
acac
bone
structur
chronic
daili
treatment
alloxaninduc
diabet
rat
consecut
day
sever
paramet
relat
bone
characterist
measur
author
report
plasma
level
osteocalcin
protein
may
use
marker
osteoblast
activ
secret
osteoblast
decreas
diabet
rat
ngml
partial
restor
upon
vo
acac
treatment
ca
ngml
though
still
lower
baselin
level
nondiabet
rat
ca
ngml
nondiabet
rat
treat
vanadium
ca
ngml
addit
treatment
diabet
rat
vo
acac
chang
bone
miner
densiti
overal
improv
normal
strength
trabecular
thick
miner
apposit
rate
background
diabet
mellitu
diabet
associ
impair
glucos
fatti
acid
metabol
induc
nonexist
insuffici
insulin
suppli
inadequ
respons
insulin
insulin
produc
langerhan
islet
pancrea
receptor
activ
glucos
synergist
fructos
stimul
secret
insulin
target
cellular
transmembran
insulin
receptor
ir
downregul
glucos
level
type
type
main
manifest
diabet
accord
estim
world
popul
suffer
diabet
type
juvenil
diabet
correspond
approxim
diabet
case
result
greatli
reduc
even
lack
product
insulin
commonli
result
autoimmun
reaction
destroy
damag
pancrea
accid
type
diabet
normal
develop
elderli
commonli
individu
insulin
still
produc
insulin
receptor
ir
tissu
cell
longer
respond
properli
insulin
mention
section
main
potenti
vanadium
treatment
diabet
probabl
come
similar
vanad
phosphat
highlight
howev
unlik
phosphat
phosphat
ester
vanad
easili
releas
bound
enzym
activ
site
addit
contrast
phosphoru
state
achiev
bind
coval
activ
center
transit
situat
vanadium
form
quit
stabl
compound
thu
bound
activ
site
vanad
easili
releas
henc
block
site
phosphat
thu
result
inhibit
respect
enzym
interestingli
known
exampl
protein
structur
vanadium
bound
activ
site
global
show
squar
pyramid
trigon
bipyramid
geometri
support
transfer
phosphoryl
group
phosphatas
phosphorylas
howev
clear
much
report
exampl
trigon
bipyramid
complex
activ
site
squar
pyramid
complex
consid
small
molecul
squar
pyramid
geometri
common
trigon
bipyramid
one
observ
support
expect
trigon
bipyramid
geometri
v
v
support
protein
prefer
squar
pyramid
geometri
interest
result
probabl
surpris
phosphatas
buildup
support
phosphat
transit
state
vanadium
compound
show
insulinlik
effect
frequent
design
insulin
mimet
im
howev
sinc
situat
residu
insulin
product
design
insulinenhanc
compound
adequ
mani
year
treatment
diabet
anim
sporad
human
individu
v
v
v
iv
compound
employ
v
iv
quit
suscept
oxid
ph
form
insolubl
hydroxid
ph
ph
oligomer
vanadium
speci
may
relev
even
concentr
low
nm
see
fig
mainli
due
low
oral
bioavail
inorgan
salt
ca
v
iv
complex
organ
ligand
extens
explor
organ
ligand
allow
finetun
vanadium
compound
respect
stabil
rate
absorb
gi
tract
appli
oral
target
intern
tissu
cell
toxic
key
compound
regard
bmov
fig
deriv
thereof
v
iv
complex
form
ethylmaltol
beov
allixin
relat
complex
kojato
pyridinon
complex
also
prospect
therapeut
sever
complex
studi
vo
acac
sever
picolinato
dipicolinato
deriv
fig
maltol
natur
occur
compound
approv
food
addit
mani
countri
bmov
beov
far
vc
subject
clinic
test
essenti
encourag
respons
sever
vc
test
cell
cultur
vitro
diabet
anim
vivo
eg
stz
rat
zucker
rat
model
diabet
respect
fig
provid
overview
uptak
distribut
vanadium
compound
human
bodi
intern
oral
vc
subject
rather
strong
acid
condit
ph
stomach
potenti
destruct
effect
acid
circumv
drug
encapsul
saliva
small
intestin
slightli
alkalin
therefor
addit
expect
speciat
origin
appli
prodrug
cross
organ
quit
distinct
ph
condit
possibl
loss
ligand
oxid
mainli
oral
caviti
reduct
mainli
gi
tract
must
consid
unavoid
situat
addit
origin
vc
may
chang
upon
interact
low
high
molecular
mass
constitu
may
behav
ligand
abundantli
present
nutrit
compon
well
bodi
fluid
secret
bodi
fluid
stimul
intak
food
fact
without
particip
ligand
vc
would
convert
simpl
compound
v
iv
salt
probabl
form
insolubl
v
iv
oh
ph
absorb
expel
fece
ii
small
intestin
thu
distribut
throughout
bodi
addit
oral
uptak
inorgan
vanadium
compound
inhal
thu
pulmonari
ingest
vanadium
oxid
present
dust
particl
anoth
possibl
rout
lung
substanti
part
vox
may
solubil
convert
vanad
thu
also
introduc
blood
stream
vanadium
coordin
compound
vo
carrier
n
organ
carrier
ligand
indic
fig
also
involv
speciat
enter
bodi
low
high
ph
loss
one
carrier
ligand
may
take
place
compound
convert
distinct
complex
inorgan
vanadium
altern
addit
bodi
ligand
l
induc
reorgan
coordin
sphere
form
vol
n
mix
carrier
l
speci
thu
chang
absorpt
properti
carrier
ligand
vo
carrier
n
compound
larg
influenc
efficaci
vanadium
compound
determin
resorpt
transport
stabil
complex
thu
bioavail
true
antidiabet
speci
possibl
vanad
underlin
advantag
bioavail
therapeut
efficaci
vo
carrier
n
compound
inde
effect
inorgan
vc
group
sakurai
test
sever
new
drug
deliveri
system
tri
direct
intestin
administr
eg
ileum
involv
entericco
capsul
ecc
gelatin
capsul
vobiopolym
acid
complex
overcom
sever
gastrointestin
absorpt
andor
irrit
problem
vanadium
inorgan
salt
administr
form
inde
improv
absorpt
ecc
deliveri
system
give
better
result
gelatin
capsul
howev
knowledg
promis
result
diabet
mice
lead
clinic
test
human
transderm
deliveri
also
tri
diabet
rat
passiv
iontophoresi
use
peroxovanadium
without
complex
increas
blood
level
vanadium
achiev
blood
glucos
reduct
report
modest
vo
carrier
n
compound
inher
suscept
hydrolysi
administr
vc
like
result
loss
ligand
extens
work
carri
aim
determin
actual
activ
speci
studi
use
bmov
beov
demonstr
upon
administr
complex
maltol
ligand
separ
metal
ion
transport
protein
transferrin
like
play
key
role
distribut
vanadium
intracellularli
due
transmetal
process
cellular
compartment
also
like
ligand
addit
transferrin
involv
biolog
effect
v
compound
thu
probabl
vc
taken
partial
complet
hydrolyz
gi
andor
blood
serum
vanadium
bind
bioligand
name
htf
either
endocytosi
diffus
anion
channel
vanad
vanadium
may
uptaken
cell
subject
speciat
redox
level
avail
subsequ
therapeut
toxic
effect
depend
sever
factor
name
amount
uptaken
type
tissu
carrier
ligand
still
present
allow
level
effect
andor
target
site
therapeut
action
case
final
intracellular
break
complex
probabl
occur
allow
display
vanadium
physiolog
effect
cell
contain
insulin
receptor
incorpor
membran
ir
tetramer
transmembran
protein
tyrosin
kinas
two
subunit
expos
outsid
two
subunit
expos
cytosol
insulin
dock
subunit
tyrosin
residu
intracellular
subunit
becom
phosphoryl
correspond
activ
cytosol
insulinsign
cascad
initi
way
involv
sever
postreceptor
event
end
activ
glucos
transport
thu
phosphoril
trigger
phosphoryl
ir
substrat
ir
intracellular
protein
contain
tyrosin
residu
activ
ir
turn
initi
signal
cascad
cours
kinas
phosphatidylinositol
protein
kinas
b
pkbakt
glycogen
synthas
activ
pkb
bind
phosphat
tyr
ser
residu
target
glucos
transport
transloc
cell
surfac
intak
glucos
cytosol
glucos
either
broken
co
h
trigger
activ
polymer
glycogen
increas
consensu
vanadatephosph
analog
relev
insulin
enhanc
action
mode
oper
vanadium
compound
wide
accept
mode
action
v
compound
thu
far
attribut
inhibit
protein
tyrosin
phosphatas
absenc
insulin
case
inadequ
insulin
respons
ir
phosphoryl
tyrosin
residu
subunit
ir
counteract
protein
tyrosin
phosphatas
result
signal
break
cellular
uptak
glucos
vanad
present
insid
cell
result
uptak
vanadium
compound
see
fig
therebi
restoringkeep
activ
signal
transduct
path
glucos
uptak
fig
possibl
confirm
eg
bmov
vo
dhp
vo
complex
inhibit
activ
phosphatidylinositol
akt
signal
enhanc
tyrosin
phosphoryl
ir
particular
case
bmov
action
review
srivastava
cowork
show
besid
better
inorgan
vcompound
induc
phosphoryl
pkb
key
upstream
transduc
bmov
probabl
transactiv
way
activ
pathway
phosphoryl
pkb
mediat
well
downstream
target
regul
glucos
transport
glycogen
synthesi
gluconeogenesi
group
cran
also
suggest
activ
ir
signal
insulin
bmov
administr
involv
increas
associ
ir
special
nanoscal
membran
microdomain
observ
insulinlik
activ
bmov
decomposit
product
would
due
chang
cellsurfac
membran
lipid
order
rather
due
direct
interact
ir
case
vo
acac
certain
whether
directli
stimul
ir
tyrosin
kinas
activ
act
indirectli
activ
tyrosin
kinas
inhibit
tyrosin
phosphatas
fact
vo
acac
report
exhibit
synerg
insulin
regul
tyr
phosphoryl
level
ir
condit
act
uncompetit
inhibitor
also
report
vo
acac
presenc
hsa
also
activ
much
voso
phosphoryl
vanad
may
bind
sever
protein
tyrosin
phosphatas
insid
cell
inhibit
action
protein
kinas
stimul
action
howev
kinas
activ
appear
involv
pharmacolog
effect
vanadium
least
autophosphoryl
insulin
receptor
phosphotyrosin
phosphatas
whether
known
bind
oatom
tyr
side
group
redox
reaction
involv
two
form
may
also
oper
consequ
process
easili
anticip
mode
action
v
compound
associ
inhibit
protein
tyrosin
phosphatas
also
relev
understand
vc
revers
inhibitor
wherea
other
irrevers
modifi
protein
redox
process
recent
review
cran
et
al
coordin
environ
vanad
bound
protein
tyrosin
phosphatas
conclud
actual
differ
coordin
environ
small
presum
less
critic
gener
anticip
interest
observ
whose
consequ
subject
discuss
easili
anticip
group
cran
et
al
also
propos
interact
vc
cellular
redox
process
import
antidiabet
effect
vc
vc
caus
increas
ro
rn
reactiv
nitrogen
speci
via
multipl
mechan
thu
altern
addit
ro
produc
vanad
v
iv
oh
h
vo
may
respons
eg
inhibit
oxid
target
cy
residu
present
cy
present
reduc
form
full
activ
group
cran
also
propos
compound
stabil
abil
interact
cellular
redox
reaction
key
aspect
insulinenhanc
activ
exert
vc
moreov
possibl
membran
interact
influenc
ligand
also
suggest
membran
effect
may
affect
uptak
action
vc
inorgan
organ
form
vanadium
test
human
subject
dose
use
normal
compar
lower
experiment
anim
thu
modest
improv
insulin
glucos
metabol
seen
within
week
upon
start
trial
major
drawback
report
gastrointestin
gi
distress
sinc
small
amount
vanadium
absorb
gener
oral
dose
major
goal
research
develop
appropri
ligand
improv
absorpt
thu
decreas
dose
requir
attenu
gastric
irrit
beov
complet
phase
advanc
phase
iia
clinic
trial
phase
trial
safeti
toler
oral
administ
increas
singl
dose
mg
mg
beov
test
nondiabet
volunt
advers
effect
found
throughout
trial
period
includ
comparison
studi
beov
voso
upon
compar
level
vanadium
intak
demonstr
increas
uptak
longer
resid
time
complex
result
report
nonlinear
pharmacokinet
bmov
oral
intak
maximum
plasma
concentr
vanadium
c
max
area
curv
auc
increas
nonproport
way
five
oral
dose
mg
appar
oral
clearanc
doseauc
decreas
significantli
dose
increas
suggest
oral
absorpt
firstpass
elimin
bmov
capacitylimit
process
gastrointestin
liver
feed
quit
neg
effect
avail
beov
suggest
ligand
substitut
food
compon
major
observ
phase
studi
safeti
toler
pharmacolog
relev
dose
beov
advers
health
effect
volunt
gastrointestin
liver
kidney
function
blood
paramet
hemoglobin
bilirubin
level
remain
within
normal
limit
throughout
studi
overal
bioavail
vanadium
beov
three
time
voso
also
consist
previou
data
obtain
anim
noteworthi
vanadium
absorpt
administr
mg
beov
fast
state
approxim
time
higher
administr
dose
fed
state
toler
compar
fed
fast
state
clinic
signific
advers
event
chang
safeti
paramet
assess
object
phase
iia
trial
assess
safeti
efficaci
mg
equival
molar
basi
mg
hydrat
voso
mg
v
daili
dose
oral
administ
beov
treatment
period
type
diabet
individu
nontreat
followup
glycosyl
hemoglobin
chang
fpg
respons
oral
glucos
toler
glycosyl
hemoglobin
percent
hemoglobin
control
outcom
paramet
includ
seven
subject
treat
beov
fast
state
two
given
placebo
control
global
posit
treatment
effect
observ
treat
patient
reduct
fast
blood
glucos
observ
compar
two
placebo
subject
respons
oral
glucos
load
gener
improv
treat
diabet
subject
compar
control
glycosyl
hemoglobin
increas
percentag
total
hemoglobin
placebo
control
treat
subject
chang
hbaic
treatment
variabl
two
patient
show
consist
decreas
accord
sever
measur
done
overal
dose
beov
given
daili
type
diabet
subject
one
month
clearli
affect
diabet
symptomatolog
term
pharmacolog
effect
emphas
one
relev
action
vanadium
monovanad
inhibit
activ
site
phosphatas
relat
enzym
involv
hydrolysi
phosphat
ester
vanadium
inde
appear
particularli
effect
inhibitor
phosphatas
deactiv
ir
kinas
activ
site
moreov
inhibit
varieti
phosphatas
control
numer
cellular
function
consequ
possibl
vanadium
may
deleteri
side
effect
dose
use
pharmacolog
studi
addit
partli
due
abil
gener
ro
also
mixtur
inhibit
enhanc
effect
sever
biolog
relev
process
exert
nonspecif
effect
differ
cell
structur
vc
mani
rout
action
sometim
diametr
opposit
name
may
antitumor
carcinogen
properti
addit
much
known
regard
effect
vc
immun
system
inflammatori
reaction
given
potenti
toxic
vanadium
biotransform
biodistribut
vanadiumcontain
drug
outmost
import
vc
would
readili
hydrolyz
gastrointestin
tract
given
oral
could
direct
specif
tissu
might
presum
overcom
mention
deleteri
side
effect
thu
potenti
vc
treat
diabet
still
open
field
ideal
avoid
least
minim
advers
side
effect
vc
may
direct
insulinsensit
tissu
adipocyt
hepatocyt
skelet
muscl
need
develop
partial
complet
hydrolysi
chelat
ligand
tissu
could
releas
bioactiv
form
local
whether
tight
connect
advers
effect
benefici
effect
solv
yet
establish
toxic
side
effect
vanadium
could
avoid
would
high
potenti
pharmacolog
interest
treatment
diabet
recent
year
anticanc
properti
vc
notic
underli
mechan
also
well
understood
main
target
antitumor
effect
vanadium
disrupt
cellular
metabol
gener
ro
alter
cellular
organel
lysosom
mitochondria
spindl
protein
actin
tubulin
signal
transduct
pathway
cyclin
caspas
turn
play
role
cell
cycl
arrest
apoptosi
moreov
cell
prolifer
also
disturb
genotox
effect
vanadium
exert
nuclei
cell
dna
damag
differ
cancer
cell
line
vc
act
inhibit
cell
prolifer
whole
rang
test
concentr
vc
evalu
potenti
antitumor
agent
identif
appropri
model
vivo
vitro
preclin
test
inhibitor
tumor
angiogenesi
progress
vital
success
develop
anticanc
therapeut
although
focu
human
molecular
target
preclin
vivo
efficaci
test
done
mice
interest
studi
hepat
preneoplasia
induc
male
spraguedawley
rat
level
modifi
dna
base
deoxyguanosin
potenti
marker
involv
initi
carcinogenesi
measur
upon
supplement
nh
vo
drink
water
dose
ppm
consecut
week
format
decreas
preneoplast
rat
liver
moreov
longterm
den
plu
pb
regimen
vanadium
limit
situ
mt
express
concomit
decreas
mt
immunoreact
treatment
nh
vo
restor
hepat
level
essenti
trace
element
decreas
nodular
incid
nodul
multipl
rat
treat
den
plu
pb
global
studi
provid
evid
support
chemoprevent
potenti
vanadium
limit
neoplast
transform
preneoplast
stage
hepatocarcinogenesi
rat
tumor
cell
deriv
human
placenta
murin
tumor
cell
line
endothelium
murin
cell
edma
inhibit
sodium
vanad
cell
activ
prolifer
sensibl
inhibitori
action
v
v
deriv
sever
vc
potenti
applic
cancer
treatment
synthes
among
v
iv
deriv
metvan
fig
identifi
one
promis
multitarget
anticanc
vc
apoptosisinduc
activ
nanomolar
low
micromolar
concentr
metvan
induc
apoptosi
differ
tumor
cell
line
human
origin
leukemia
cell
multipl
myeloma
cell
solid
tumor
cell
deriv
glioblastoma
breast
cancer
ovarian
prostat
testicular
cancer
patient
anoth
advantag
metvan
highli
effect
ovarian
cancer
testicular
cancer
cell
line
resist
cisplatin
action
probabl
associ
gener
ro
deplet
glutathion
togeth
loss
mitochondri
transmembran
potenti
metastat
properti
tumor
cell
human
malign
glioblastoma
breast
cancer
also
highli
inhibit
impair
metvan
moreov
metvan
show
advantag
signific
antitumor
activ
delay
tumor
progress
increas
surviv
time
model
sever
combin
immunodefici
mous
xenograft
human
malign
glioblastoma
breast
cancer
broad
spectrum
anticanc
activ
metvan
togeth
favor
pharmacodynam
featur
lack
toxic
emphas
v
iv
compound
potenti
first
vanadium
complex
altern
platinumbas
chemotherapi
hand
vanadaand
niobatricarbadecaboranyl
monohalid
complex
prove
potent
cytotox
agent
murin
human
leukemia
lymphoma
growth
well
hela
suspend
uterin
carcinoma
vanadium
complex
decreas
prolifer
sever
tumor
cell
line
kb
nasopharynx
hepe
liver
ileum
ovari
solid
carcinoma
human
promyelocyt
leukemia
cell
compound
reduc
growth
kb
nasopharynx
hepe
liver
ileum
ovari
solid
carcinoma
cell
dna
purin
de
novo
synthes
significantli
inhibit
suppress
activ
dna
polymeras
alpha
prppamido
transferas
activ
topoisomeras
ii
inhibit
complex
activ
caspas
convey
cell
apoptosi
anoth
interest
group
compound
antitumor
properti
three
vanadocen
deriv
see
eg
fig
induc
apoptosi
human
cancer
cell
yet
unknown
mechan
human
cell
sever
vanadocen
complex
trigger
activ
cfo
promot
without
affect
minimum
promot
contain
respons
element
promot
result
indic
apoptot
signal
vanadocen
trigger
primari
dna
damag
requir
induct
therebi
disprov
hypothesi
mechanist
resembl
cytotox
action
cisplatin
hand
vanadocen
effici
agent
human
testicular
cell
line
systemat
studi
sever
metallocen
contain
vanadium
vanadocen
well
sever
metal
test
human
testicular
cancer
cell
line
interestingli
v
iv
contain
metallocen
exhibit
signific
cytotox
lead
tumor
cell
apoptosi
within
h
protect
biomolecul
attack
free
radic
andor
suppress
result
injur
numer
natur
free
radic
scaveng
antioxid
among
antirad
flavonoid
group
natur
occur
polyphenol
predominantli
synthes
higher
plant
chemic
flavonoid
gener
structur
correspond
fig
skeleton
consist
two
phenyl
ring
b
one
heterocycl
ring
c
carbon
structur
frequent
abbrevi
metal
chelat
may
import
role
improv
antioxid
properti
antitumor
behavior
flavonoid
bind
influenc
antioxid
antitumor
properti
flavonoid
phenol
oh
substitu
electron
reson
aand
b
ring
flavonoid
basi
antioxid
biolog
activ
besid
oh
group
locat
b
ring
signific
factor
influenc
scaveng
properti
toward
reactiv
oxygen
speci
ro
antioxid
antitumor
properti
seri
flavonoid
quercetin
hesperidin
morin
silibinin
chrysin
complex
oxidovanadium
iv
investig
model
two
murin
osteoblast
cell
line
cultur
quercetin
display
antitumor
properti
sinc
caus
inhibit
cell
prolifer
tumor
cell
line
show
deleteri
action
nontransform
osteoblast
nevertheless
v
iv
complex
deleteri
tumor
osteoblast
v
iv
complex
hesperidin
test
osteosarcoma
cell
line
well
human
colon
adenocarcinoma
show
promissori
anticarcinogen
properti
morin
also
natur
compound
attract
healthi
properti
epidemiolog
studi
alreadi
indic
adequ
intak
flavonoidrich
food
may
reduc
risk
coronari
heart
diseas
certain
cancer
antioxid
anticanc
activ
morin
improv
capac
investig
chelat
oxidovanadium
iv
antiprolif
effect
morpholog
chang
ro
gener
normal
mous
tumor
rat
bone
cell
line
cultur
studi
morin
v
iv
complex
behav
good
antioxid
agent
radic
complex
improv
behavior
consider
variat
sensit
observ
breast
cancer
cell
nonspecif
found
treatment
osteosarcoma
moreov
compound
affect
normal
prolifer
breast
epitheli
mammal
cell
mechanist
studi
demonstr
complex
gener
ro
produc
damag
dna
plasmat
membran
observ
damag
cell
line
contrast
perturb
mitochondri
membran
potenti
activ
caspas
breast
tumor
cell
reveal
apoptot
cell
death
process
moreov
two
new
complex
flavonoid
oxidovanadium
iv
thoroughli
investig
cell
line
good
model
osteosarcoma
common
form
bone
cancer
studi
effect
potenti
anticanc
drug
silibinin
silybin
one
popular
dietari
supplement
extens
studi
antioxid
hepatoprotect
anticanc
properti
silibinin
also
demonstr
potent
antiprolif
effect
variou
malign
cell
line
report
rat
osteosarcoma
cell
line
silibinin
caus
decreas
cell
prolifer
ca
effect
nontransform
osteoblast
less
concentr
human
osteosarcoma
cell
line
v
iv
complex
na
v
iv
silibinin
vosil
inhibit
viabil
osteosarcoma
cell
dose
depend
manner
greater
potenc
silibinin
inorgan
v
iv
vosil
also
display
concentr
effect
cytoand
genotox
process
distribut
redox
statu
cell
determin
increas
ro
level
decreas
gshgssg
ratio
main
event
involv
deleteri
effect
complex
tumor
osteosarcoma
cell
moreov
complex
caus
cell
cycl
arrest
activ
caspas
trigger
apoptosi
compar
antitumor
effect
vosil
refer
metallodrug
cisplatin
cell
lower
test
concentr
cisplatin
vosil
effect
cell
viabil
b
cisplatin
vosil
similar
inhibitori
agent
cell
prolifer
sinc
produc
ca
decreas
cell
viabil
c
middl
test
concentr
vosil
less
deleteri
cisplatin
versu
surviv
wherea
differ
versu
surviv
cell
respect
anoth
interest
flavonoid
complex
potenti
antitumor
properti
chrysin
comparison
antitumor
action
vochri
vosil
cisplatin
human
osteosarcoma
cell
line
could
conclud
vochri
strongest
antiprolif
agent
ro
alter
gshgssg
ratio
relev
main
mechan
action
vochri
oxid
stress
diminish
addit
ro
scaveng
vitamin
c
plu
vitamin
e
gsh
viabil
experi
demonstr
benefici
effect
besid
vochri
caus
disrupt
mitochondria
membran
potenti
mmp
increas
level
caspas
produc
dna
fragment
measur
peak
cell
cycl
arrest
experi
event
final
convey
human
osteosarcom
cell
apoptosi
sever
organ
chelat
vanadium
compound
potenti
pharmacolog
action
simpl
vanadium
salt
exampl
vanadium
complex
quinolin
pyridinon
ligand
synthes
test
antiprolif
activ
toward
cell
antiprolif
activ
quinolin
complex
toward
cell
show
littl
depend
length
shape
alkyl
chain
contrast
good
correl
found
ic
valu
partit
coeffici
log
p
valu
pyridinon
complex
one
member
latter
group
show
ic
valu
smaller
cisplatin
besid
complex
trigger
apoptosi
pathway
independ
caspas
activ
sinc
inhibitor
affect
antiprolif
activ
complex
vo
acac
report
block
cell
cycl
progress
perman
phase
doseand
timedepend
manner
cell
evidenc
growth
regulatori
signal
stage
neither
h
level
increas
perhap
surprisingli
level
phosphoryl
extracellular
signalregul
protein
kinas
erk
akt
highli
activ
global
author
suggest
vo
acac
prolifer
inhibit
caus
cell
cycl
arrest
result
decreas
level
phosphoryl
prb
activ
hypophosphoryl
form
via
highli
activ
erk
signal
cell
result
present
provid
new
insight
develop
vanadium
compound
potenti
anticanc
agent
vanadium
iii
lcystein
compound
show
signific
antitumor
effect
induc
soft
tumor
v
iii
cy
compound
oxid
product
concentr
show
inhibit
nep
activ
potent
thiorphan
v
iv
oso
concentr
exhibit
less
inhibitori
activ
thiorphan
addit
antimetastat
effect
v
iii
cy
compound
cy
v
iv
oso
examin
wistar
rat
treat
result
reveal
prevent
significantli
lung
metastas
anim
treat
v
iii
cy
compound
show
metastas
wherea
rat
control
group
treat
cy
v
iv
oso
exhibit
metastas
sever
v
v
complex
screen
potenti
cytotox
activ
two
differ
cell
line
toxic
effect
incub
time
concentr
depend
specif
compound
type
cell
hela
tumor
cell
sensit
drug
effect
fibroblast
accord
ic
valu
result
revers
drug
effect
v
v
mhcpe
system
mhcpe
fig
show
higher
toxic
tumor
cell
nontumor
cell
indic
potenti
antitumor
activ
anoth
interest
group
vanadium
compound
complex
oxidovanadium
iv
ligand
hold
multipl
donor
atom
abl
coordin
metal
center
strong
chelat
ligand
import
live
system
sinc
facilit
uptak
transport
metal
insid
cell
role
lowmolecularmass
compound
involv
multident
oxygen
donor
great
valu
oxodiacet
oda
ch
coo
versatil
ligand
sinc
donor
atom
place
differ
orient
oda
hold
ooo
donor
group
coordin
metal
ion
form
chelat
ring
vanadium
compound
absorb
mammal
store
mainli
bone
halflif
ca
day
result
enhanc
scientif
interest
biolog
effect
vanadium
hard
tissu
v
iv
ocomplex
oda
v
iv
oda
well
v
iv
oda
bipi
v
iv
oda
phen
fig
display
import
effect
bone
relat
cell
cultur
compound
test
two
osteoblastlik
cell
line
cultur
deriv
mous
calvaria
deriv
rat
osteosarcoma
cell
v
iv
oda
caus
inhibit
cellular
prolifer
cell
line
cytotox
stronger
normal
tumor
osteoblast
compound
also
produc
effect
cell
differenti
test
specif
activ
alkalin
phosphatas
cell
express
high
activ
enzym
vanadium
compound
v
iv
oda
behav
inhibitori
agent
osteoblast
differenti
besid
dosedepend
decreas
cell
prolifer
v
iv
oda
caus
morpholog
actin
alter
v
iv
oda
increas
level
ro
correl
decreas
gshgssg
ratio
besid
v
iv
oda
induc
dissip
mitochondria
membran
potenti
mmp
promot
increas
erk
cascad
phosphoryl
involv
regul
cellular
death
surviv
effect
pronounc
cell
use
specif
inhibitor
differ
intracellular
signal
pathway
could
demonstr
v
iv
oda
stimul
erk
phosphoril
induct
upstream
kinas
erk
pathway
free
radic
clearli
result
suggest
apoptot
action
complex
mediat
involv
oxid
stress
mmp
alter
erk
pathway
moreov
relat
vo
oda
phen
osteoblast
model
caus
inhibit
cellular
prolifer
cell
line
cytotox
stronger
normal
tumor
osteoblast
contrari
vo
oda
bipi
statist
stronger
tumor
cell
recent
effect
vo
oda
vo
oda
bipi
vo
oda
phen
fig
human
osteosarcoma
cell
line
report
three
complex
depict
fig
caus
concentr
depend
inhibit
cell
viabil
antiprolif
action
could
observ
whole
rang
concentr
show
decreas
cell
viabil
higher
concentr
vo
oda
phen
caus
strong
cytotox
affect
lysosom
mitochondria
metabol
lowest
test
dose
vo
oda
vo
oda
bipi
produc
effect
higher
concentr
dna
damag
could
detect
comet
assay
vo
oda
vo
oda
phen
vo
oda
bipi
induc
dna
damag
respect
p
ro
level
increas
vo
oda
phen
vo
oda
vo
oda
bipi
moreov
vo
oda
phen
vo
oda
bipi
trigger
apoptosi
relev
mechan
cell
death
nucleas
activ
three
compound
reveal
dna
cleavag
caus
vo
oda
bipi
vo
oda
similar
vo
oda
phen
show
stronger
effect
within
seri
compound
good
relationship
bioactiv
complex
structur
notic
vo
oda
phen
present
potent
antitumor
action
human
osteosarcoma
cell
follow
vo
oda
bipi
vo
oda
accord
number
intercal
heterocycl
moieti
sever
v
v
compound
report
exhibit
antitumor
properti
variou
experiment
system
korbecki
et
al
critic
review
case
one
interest
report
use
vitro
vivo
model
character
antitumor
properti
v
v
complex
hydroxilamido
amino
acid
fig
complex
vo
nh
val
vo
nh
met
inhibit
prolifer
two
osteoblast
cell
line
cultur
differ
potenc
besid
complex
deleteri
viabil
vivo
model
zebrafish
egg
good
correl
vitro
vivo
experi
support
ic
valu
complex
consid
result
osteoblast
studi
ic
valu
obtain
vivo
model
toxic
fet
test
moreov
cytotox
cell
cultur
show
decreas
mitochondri
enzymat
activ
dna
damag
could
also
observ
comet
format
cell
effect
could
observ
osteosarcoma
cell
addit
vo
nh
val
greatli
fig
structur
v
v
hydroxylamidoamino
acid
complex
enhanc
ro
level
cell
suggest
import
role
oxid
stress
toxic
mechan
compound
sinc
vo
nh
val
stabl
well
less
cytotox
cell
cultur
vivo
model
vo
nh
met
consid
promissori
compound
investig
potenti
antitumor
agent
moreov
result
emphas
potenti
zebrafish
attract
complementari
platform
drug
develop
global
result
concern
antitumor
properti
vc
promis
respect
possibl
introduct
therapi
due
low
ic
sever
depend
cell
line
vc
antiprolif
proapoptot
effect
mani
possibl
target
vc
text
review
korbecki
et
al
refer
therein
summar
relev
data
hand
vc
may
also
carcinogen
properti
stimul
tumor
develop
well
antiapoptot
properti
cancer
cell
thu
sever
mechan
also
exist
vc
present
carcinogen
action
effect
vanadium
compound
depend
mani
factor
name
proapoptot
antiapoptot
effect
vc
depend
larg
cell
type
also
type
vc
dose
key
protein
defect
may
drastic
chang
effect
vc
larg
number
tumor
cell
type
defect
gene
encod
protein
cell
tumor
cell
nontumor
cell
vc
inhibit
cell
cycl
thu
induc
apoptosi
activ
nfb
ro
gener
vc
enhanc
apoptot
effect
contrast
cell
disturb
phosphoryl
lead
inhibit
apoptosi
addit
vc
stimul
cell
cycl
thu
inhibit
apoptosi
process
mutual
connect
moreov
nfb
activ
inhibit
apoptosi
tumor
cell
one
relev
issu
frequent
vc
caus
much
dna
damag
tumor
cell
compar
nontumor
cell
present
level
extens
dna
damag
lead
apoptosi
tumor
cell
less
intens
damag
evok
vanadium
compound
nontumor
cell
may
stimul
synthesi
activ
repair
enzym
thu
protect
cell
apoptosi
process
promot
tumor
cell
growth
earli
stage
diseas
antitumor
effect
advanc
stage
cancer
fact
studi
anim
treat
carcinogen
suggest
vc
use
low
level
select
effect
tumor
cell
comprehens
review
current
statu
potenti
vanadium
compound
treatment
neglect
tropic
diseas
background
publish
work
review
research
carri
till
end
vc
prospect
agent
trypanosoma
cruzi
leishmania
spp
entamoeba
histolytica
protozoan
parasit
caus
agent
american
trypanosomiasi
chaga
diseas
leishmaniasi
amoebiasi
respect
brief
descript
diseas
includ
thu
recommend
refer
purpos
review
kickoff
relat
work
follow
inclus
topic
recent
review
themat
chapter
present
review
includ
work
carri
topic
although
research
effort
medicin
chemistri
vanadium
mainli
focus
whether
improv
biodistribut
toler
vanadium
insulinenhanc
core
develop
potenti
antitumor
compound
recent
year
research
group
dedic
effort
develop
prospect
agent
toward
potenti
treatment
parasit
diseas
produc
trypanosomatid
e
histolityca
parasit
vanadium
compound
evalu
vitro
relat
protozoan
parasit
trypanosoma
brucei
also
address
current
review
human
african
trypanosomiasi
sleep
sick
caus
parasit
brucei
complex
eg
brucei
gambiens
brucei
rhodesiens
transmit
bite
tsets
fli
repres
major
diseas
burden
subsaharan
region
africa
also
consid
world
health
organ
one
seventeen
neglect
tropic
diseas
togeth
chaga
diseas
leishmanias
diseas
affect
mostli
poor
popul
live
remot
rural
area
africa
untreat
usual
fatal
although
control
diseas
reemerg
due
lack
sustain
surveil
recent
upon
increas
control
number
new
report
case
diminish
slowli
four
drug
regist
treatment
human
african
trypanosomiasi
pentamidin
suramin
melarsoprol
eflornithin
give
rise
undesir
collater
toxic
effect
show
limit
variabl
efficaci
depend
type
stage
diseas
suffer
parasit
develop
resist
respect
antit
cruzi
agent
typic
medicin
chemistri
research
carri
ration
design
prospect
antitrypanosom
compound
could
hit
lead
compound
drug
develop
research
involv
design
two
famili
v
iv
ocompound
includ
polypyridyl
ligand
nn
bear
dna
intercal
capac
fig
strategi
point
dna
potenti
parasit
target
inspir
fact
compound
abl
gener
nucleic
acid
modif
receiv
high
attent
antitumor
drug
design
report
metabol
similar
tumor
cell
highli
prolif
trypanosomatid
parasit
instanc
compound
effici
interact
dna
interc
mode
exert
antitrypanosom
activ
strategi
two
famili
structur
relat
compound
synthes
fulli
character
evalu
tabl
nn
ligand
show
activ
parasit
coordin
v
iv
core
led
activ
rang
refer
tripanocid
drug
nifurtimox
ic
slight
chang
activ
dppz
phendion
epoxyphen
complex
noteworthi
tdzp
complex
show
significantli
improv
antitrypanosom
activ
respect
free
tdzp
although
complex
structur
analog
natur
nn
ligand
includ
coordin
sphere
determin
antitrypanosom
activ
atom
forc
microscopi
afm
studi
use
plasmid
model
molecul
confirm
complex
modifi
tertiari
structur
plasmid
indic
interact
dna
fig
although
reduc
seri
structur
relat
compound
compar
afm
studi
alon
enough
judg
abil
compound
affect
dna
correl
antit
cruzi
activ
intens
effect
observ
plasmid
appear
exist
addit
parasit
target
could
affect
complex
due
presenc
v
iv
core
although
demonstr
hypothes
coordin
vanadium
may
way
improv
bioavail
act
carrier
system
improv
cell
uptak
due
chang
solubl
andor
lipophil
phenanthrolin
deriv
upon
coordin
larger
seri
heterolept
bioactiv
v
iv
nn
compound
obtain
l
trident
salicylaldehyd
semicarbazon
deriv
depict
fig
nn
either
bipi
dppz
phen
epoxyphen
aminophen
seri
includ
sever
compound
interest
biolog
properti
vitro
antit
cruzi
activ
result
mainli
depend
natur
nn
ligand
almost
independ
chemic
natur
substitu
r
r
salicylaldehyd
moieti
tabl
valu
submicromolar
rang
activ
aminophen
measur
ic
valu
unit
select
parasit
respect
mammalian
cell
also
studi
relev
compound
phen
compound
show
select
index
si
ic
mammalian
cell
model
cruzi
rang
use
human
acut
monocyt
leukemia
atcc
cell
mammalian
cell
model
epoxyphen
aminophen
compound
show
si
valu
ic
murin
macrophages
cruzi
rang
respect
furthermor
none
aminophen
complex
display
relev
toxic
macrophag
dose
depict
case
much
higher
si
valu
correspond
valu
aminophen
accord
accept
guidelin
develop
antit
cruzi
drug
compound
deserv
studi
establish
therapeut
potenti
twentyf
structur
relat
compound
qsar
quantit
structur
activ
relationship
studi
studi
carri
get
design
guid
antitrypanosom
drug
develop
studi
particularli
relev
sinc
qsar
studi
still
common
inorgan
medicin
chemistri
research
due
difficulti
get
high
number
structur
relat
compound
lipophil
effect
among
factor
control
transport
interact
biolog
receptor
lipophil
experiment
determin
use
reversedphas
tlc
experi
stationari
phase
precoat
tlcc
may
consid
simul
lipid
biolog
membran
receptor
mobil
phase
meoh
dmf
trishcl
buffer
ph
vvv
resembl
aqueou
biolog
milieu
indic
variabl
col
take
account
potenti
differ
biolog
behavior
select
nn
scaffold
highli
electrophil
epoxyphen
may
react
biolog
nucleophil
protein
dna
epoxidemoieti
nucleophil
aminophen
may
react
biolog
electrophil
aminomoieti
moreov
expand
system
dppz
phen
phen
deriv
may
also
intercal
dna
summari
equat
highlight
relev
lipophil
paramet
desir
bioactiv
addit
also
reflect
signific
structur
coligand
antit
cruzi
effect
accordingli
complex
dnamodifi
coligand
higher
col
valu
ie
aminophen
epoxyphen
cytotox
parasit
parabol
relationship
biolog
respons
lipophil
obtain
correl
optimum
r
valu
determin
may
design
guid
futur
develop
new
compound
bear
better
biolog
profil
tri
access
mechan
action
compound
dna
interact
complex
assess
differ
techniqu
agaros
gel
electrophoresi
viscos
measur
dna
solut
afm
addit
metabolom
studi
perform
incub
parasit
two
activ
v
iv
ocompound
particular
consumpt
glucos
trypanosomatid
protozoa
character
excret
reduc
product
succin
pyruv
lactat
anerobiosi
also
aerob
condit
compartment
glycolyt
enzym
place
organel
call
glycosom
rel
inefficaci
respiratori
chain
describ
previou
research
cruzi
epimastigot
metabol
use
c
glucos
substrat
describ
detect
c
nmr
carboxyl
succin
pyruv
acet
lactat
amino
acid
ala
gli
main
catabolit
glucos
therefor
modif
excret
metabolit
produc
incub
parasit
select
v
iv
ocompound
follow
h
nmr
spectroscopi
increment
excret
gli
acet
ala
observ
acet
gli
catabolit
produc
parasit
singl
mitochondrion
alanin
produc
cytosol
parasit
cell
pyruv
origin
specif
parasit
organel
call
glycosom
via
phosphoenolpyruv
pyruv
also
use
mitochondrion
likekreb
cycl
fig
consequ
increment
amount
ala
could
indic
increment
cytosol
pyruv
due
defici
mitochondrion
uptak
emerg
deleteri
effect
mitochondrion
integr
consequ
mitochondrion
could
point
potenti
target
complex
presenc
v
iv
core
togeth
semicarbazon
nn
coligand
seem
determin
activ
v
v
lh
complex
l
salicylaldehyd
semicarbazon
deriv
show
antitrypanosom
activ
concern
question
vanadium
center
need
order
bioactiv
compound
previous
obtain
compound
aromat
amin
noxid
deriv
show
significantli
higher
activ
v
iv
ocompound
analog
cu
ii
pd
ii
compound
result
agreement
previous
describ
observ
suggest
complex
probabl
interact
dna
also
affect
relev
metabol
pathway
parasit
recent
genom
parasit
cruzi
brucei
leishmania
major
decod
show
high
degre
similar
thu
clinic
use
drug
affect
common
enzymat
target
metabol
pathway
trypanosomatid
parasit
sought
emerg
broadspectrum
chemic
scaffold
could
offer
innov
less
expens
approach
antiparasit
drug
discoveri
therefor
v
iv
ocompound
describ
also
test
either
v
iv
dppz
compound
l
fig
show
dose
depend
growth
inhibitori
activ
toward
infect
form
brucei
brucei
strain
cell
line
show
ic
valu
low
micromolar
rang
respect
hand
bipi
analog
complex
show
signific
activ
parasit
seri
show
similar
behavior
cruzi
brucei
result
encourag
respect
propos
strategi
develop
compound
could
show
activ
toward
genet
relat
parasit
use
similar
strategi
mixedligand
bioactiv
v
iv
ocompound
develop
includ
phen
coligand
purpos
semicarbazon
ono
coligand
chang
ono
nno
trident
compound
case
complex
depict
fig
mixedligand
v
iv
complex
show
improv
ic
cruzi
respect
ligand
ic
ic
valu
order
nifurtimox
ic
complex
almost
ten
time
activ
v
v
explain
high
inhibitori
activ
parasit
compar
interact
compound
dna
due
presenc
phen
ligand
postul
fig
hypothes
higher
activ
vc
may
relat
either
easier
uptak
andor
higher
efficaci
toward
target
hand
insid
cell
vanadium
speciat
may
yield
speci
contain
origin
ligand
phen
moieti
may
inde
relev
respect
sinc
improv
biolog
activ
metalbas
system
probabl
act
dna
intercal
inde
dna
interact
abil
phen
complex
demonstr
afm
fluoresc
spectroscopi
viscos
measur
two
addit
recent
report
vc
bear
inhibitori
effect
leishmania
spp
growth
one
establish
growth
inhibit
l
tarentola
promastigot
vitro
due
decavanad
nh
v
author
suggest
inhibit
phosphatas
probabl
mechan
action
report
involv
complet
differ
strategi
mammalian
host
leishmania
parasit
live
insid
macrophag
resist
leishmania
heal
abil
leishmaniasi
relat
respons
macrophag
thu
compound
activ
macrophag
pathway
could
show
interest
leishmanicid
activ
context
nativ
chemic
modifi
polysaccharid
studi
potenti
immun
respons
previou
research
author
show
v
iv
complex
galactomannan
gmpoli
isol
lichen
ramalina
celastri
exacerb
cytotox
intracellular
leishmania
vitro
effect
galactomannan
galmana
isol
seed
mimosa
scabrella
oxidovanadium
ivv
complex
macrophag
activ
leishmanicid
activ
leishmania
l
amazonensi
intramacrophag
amastigot
confirm
potent
activ
macrophag
favor
upregul
respons
macrophag
respons
leishmanicid
effect
respect
vc
prospect
agent
treatment
amoebiasi
maurya
et
al
develop
larg
seri
vanadium
compound
activ
e
histolytica
discuss
previou
review
expand
work
new
seri
v
iv
oand
v
v
complex
binucl
bi
dibas
trident
on
donor
ligand
system
show
antiamoeb
activ
report
fig
synthes
v
v
complex
along
ligand
screen
antiamoeb
activ
vitro
common
imss
highli
virul
strain
e
histolytica
complex
ligand
show
ic
scarc
work
also
report
vanadium
compound
show
activ
certain
virus
bacteria
fungi
antihiv
vanadium
complex
effect
vc
human
immun
defici
viru
hiv
review
sun
et
al
studi
show
vanadiumthiourea
complex
vanadium
substitut
polyoxotungst
exhibit
potent
antihiv
properti
toward
infect
immort
tcell
particular
vanadiumsubstitut
polyoxidotungst
v
iv
v
v
sbw
exhibit
antivir
activ
vitro
also
virus
caus
influenza
dengu
fever
sar
sever
acut
respiratori
syndrom
physiolog
condit
keggin
sandwich
decompos
vanad
v
tungstat
vi
suggest
real
activ
speci
known
v
iv
complex
much
stabl
physiolog
condit
porphyrinato
ligand
use
stabil
v
iv
ounit
get
watersolubl
oxidovanadium
iv
porphyrin
porphyrin
rigid
squar
planar
scaffold
could
prohibit
demetal
reaction
v
iv
porphyrin
prepar
stabl
gsh
contain
solut
inhibitori
effect
bal
replic
cell
evalu
complex
show
antivir
activ
compar
vehicl
control
one
water
solubl
contain
aminosulfonyl
function
group
fig
exhibit
highest
potenc
level
inhibit
revers
transcriptas
rt
one
major
target
antihiv
drug
bind
vc
rt
report
inhibitori
power
toward
measur
use
elisa
method
signific
rt
inhibit
observ
min
incub
compar
drugfre
control
comput
stimul
interact
v
iv
porphyrin
complex
differ
molecular
target
reveal
show
preferenti
bind
protein
bind
energi
suggest
may
exhibit
activ
block
entranc
viru
target
host
cell
eg
oxidovanadium
iv
cyclam
complex
also
develop
potenti
antihiv
agent
xylylbicyclam
complex
fig
highli
activ
iiib
rod
strain
ic
valu
rang
howev
oligomer
v
iv
ocyclam
complex
show
inact
author
propos
bind
complex
receptor
protein
hiv
use
infect
lymphocyt
call
chemokin
receptor
type
mechan
antivir
action
dock
studi
activ
compound
show
bind
model
human
receptor
might
occur
via
coordin
vanadium
carboxyl
protein
accompani
weak
attract
interact
oxidovanadium
moieti
trp
hydrophob
interact
tryptophan
residu
bicyclam
ring
epr
data
aqueou
solut
reveal
two
differ
environ
v
iv
center
exchang
axial
sulfato
chlorid
ligand
solvent
differ
natur
v
iv
speci
present
probabl
reason
distinct
biolog
activ
chlorido
sulfato
complex
vanadium
compound
show
activ
vitro
virus
respons
viral
infect
influenza
dengu
fever
sar
previous
review
instanc
antivir
activ
observ
vanad
depend
haloperoxidas
isol
alga
corallina
inaequali
mutant
high
activ
report
envelop
herp
simplex
nonenvelop
virus
coxsackieviru
addit
activ
gramposit
staphylococcu
aureu
gramneg
bacteria
pseudomona
aeruginosa
observ
fig
activ
mic
enhanc
bind
v
iv
ocor
result
unspecif
cytotox
mammalian
cell
model
report
good
biolog
result
recent
obtain
v
iv
v
v
homolept
complex
heterolept
one
includ
picolinato
schiff
base
coligand
privileg
structur
present
mani
bioactiv
natur
product
use
pharmacophor
design
bioactiv
compound
differ
diseas
shown
work
also
antimtb
activ
test
pansuscept
tuberculosi
atcc
strain
complex
fig
show
low
mic
valu
inhibit
similar
mic
qualifi
potenti
antimtb
agent
lower
mic
drug
commonli
use
treat
tuberculosi
activ
mtb
author
suggest
nonspecif
mechan
action
inclus
ligand
vc
might
improv
bioavail
enhanc
abil
penetr
lipidrich
hydrophob
cell
wall
mycobacteria
activ
vanadium
compound
bacteria
fungi
activ
vc
bacteria
fungi
also
report
repres
exampl
includ
antibacteri
activ
differ
polyoxometal
pm
helicobact
pylori
gramneg
bacterium
princip
gastric
pathogen
human
investig
compound
evalu
drugssuscept
resist
h
pylori
strain
among
studi
compound
polyoxometal
kegginstructur
k
siv
v
w
show
bacteriostat
activ
ciprofloxacin
quinolon
type
antibiot
target
dna
topoisomeras
gyras
bacteri
type
ii
heterolept
v
iv
ocomplex
antibiot
ligand
variou
amino
acid
dlala
ltyr
ltrp
lglu
lleu
evalu
gramposit
aureu
baccilu
subtili
serratia
marcescen
gramneg
p
aeruginosa
escherichia
coli
bacteria
case
signific
increas
antibacteri
activ
ciprofloxacin
due
complex
observ
metal
complex
schiff
base
deriv
condens
test
vitro
antibacteri
activ
gramposit
bacteria
aureu
k
pneumonia
l
monocytogen
gramneg
bacteria
e
coli
p
aeruginosa
salmonella
typhimurium
antifung
activ
candida
albican
aspergillu
flavu
strain
coordin
metal
ion
particular
v
iv
ocent
vo
h
led
increas
antibacteri
antifung
activ
v
iv
ocomplex
schiff
base
deriv
condens
phenylsubstitut
phenyl
show
higher
vitro
antifung
aspergillu
niger
colletotrichum
falcatum
colletotrichum
pallesc
antibacteri
gramneg
escherichia
coli
salmonella
typhi
gramposit
aureu
bacillu
subtili
activ
free
ligand
vanadium
relev
sever
biolog
process
mani
complex
organ
deriv
propos
treatment
sever
type
diseas
although
compound
present
use
clinic
name
review
report
mani
previou
public
vanadium
compound
propos
treatment
diabet
cancer
diseas
caus
parasit
antivir
antibacteria
use
divers
type
therapeut
use
cardioprotect
improv
cardiac
perform
substanti
progress
respect
speciat
vc
blood
serum
lot
remain
done
concern
situ
realtim
investig
fate
vc
fact
besid
question
speciat
gastrointestin
tract
even
small
vc
expect
simpli
diffus
membran
get
target
tissu
must
undergo
transloc
bloodstream
endothelium
capillari
interstiti
fluid
bind
transferrin
andor
albumin
might
relev
respect
research
must
address
mechan
process
might
occur
thu
deeper
knowledg
vivo
speciat
vc
help
better
understand
mechan
transport
target
mode
action
give
support
design
effici
vanadiumbas
drug
despit
mani
advanc
yet
wellestablish
mode
action
vc
remain
challeng
mani
report
therapeut
effect
relat
similar
vanad
phosphat
thu
inhibit
activ
site
phosphatas
relat
enzym
result
thereof
kinas
activ
may
also
relev
well
abil
gener
ro
discuss
mani
public
vanadium
compound
activ
numer
signal
pathway
transcript
factor
simultan
potenti
applic
vanadium
compound
therapeut
also
exert
nonspecif
diametr
opposit
effect
differ
cell
structur
addit
still
much
known
regard
global
toxic
issu
effect
vc
immun
system
inflammatori
reaction
particularli
longterm
administr
requir
potenti
carcinogen
correl
use
vc
effect
freerad
cell
background
also
issu
address
global
vanadium
compound
potenti
pharmacolog
interest
treatment
diabet
assum
toxic
side
effect
overcom
drug
given
oral
readili
hydrolyz
gastrointestin
tract
could
direct
specif
tissu
might
possibl
overcom
certain
deleteri
side
effect
thu
use
vc
treat
type
diabet
still
open
question
given
import
cancer
parasiticrel
diseas
amoebiasi
chaga
nonadequaci
increas
resist
pathogen
present
use
therapi
potenti
lower
cost
vanadiumbas
drug
prospect
use
vc
area
appear
promis
combin
vc
drug
enhanc
therapeut
effect
also
area
deserv
much
attent
abil
overcom
balanc
exist
therapeut
action
advers
effect
exert
vc
shift
balanc
toward
benefici
side
crucial
issu
futur
use
vanadium
compound
medicin
